Wintac Peer Comparison

BSE: 524758

₹341.60

₹1.05 (0.31%)

As on 17-Dec-2020IST

Market cap

₹342 Cr

Revenue (TTM)

₹145 Cr

P/E Ratio

23.6

P/B Ratio

-48.8

Div. Yield

0 %

Edit

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	342	37,544	27,726	26,649	27,952
Revenue (₹ Cr)	145	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	14.49	414.00	288.22	387.35	-371.81
Net Margin (%)	9.59	11.23	14.79	26.01	-3.93
RoE (%)	--	8.38	29.77	25.18	-3.85
Price to Earnings	23.63	91.79	96.20	69.00	--
Price-To-Book	-48.85	7.46	20.66	15.44	3.49

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	144.96	2,708.00	314.72	340.61	6,314.90
Total Income	151.11	2,840.00	324.85	341.99	6,479.01
Total Expenditure	124.87	2,771.00	223.05	260.45	4,886.94
EBITDA	20.09	-63.00	91.67	80.15	1,427.96
Depreciation	9.22	246.00	29.31	4.19	545.04
EBIT	10.87	-309.00	62.36	75.96	882.92
Interest	2.85	249.00	9.37	5.62	163.45
Other Income	6.16	132.00	10.13	1.38	164.11
Exceptional Items	--	-142.00	--	--	18.23
Profit before Tax	14.18	-568.00	63.12	71.73	949.05
Provision for Tax	-0.31	-271.00	32.43	17.73	114.02
Profit after Tax	14.49	-297.00	30.69	54.00	835.03

Liabilities (₹ Cr)

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	5.27	3,376.00	374.15	166.93	5,605.00
Minority Interest	--	383.00	0.00	--	--
Non-Current Liabilities	14.59	496.00	52.94	80.29	2,560.38
Current Liabilities	156.62	3,121.00	111.16	166.04	2,590.70
Total Liabilities	184.64	7,746.00	538.25	413.27	10,777.71

Assets (₹ Cr)

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	108.81	4,951.00	201.99	190.83	7,006.96
Current Assets	67.67	2,281.00	336.26	216.23	3,749.12
Total Assets	184.64	7,746.00	538.25	413.27	10,777.71
Total Debt*	21.71	2,332.00	93.28	136.64	2,910.19
Net Current Assets	-88.95	-840.00	225.10	50.19	1,158.42
Contingent Liabilities	11.29	639.00	30.36	0.00	29.98

Cashflow (₹ Cr)

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	17.01	-287.00	56.87	27.96	597.58
Cash Flow from Investing Activities	-7.19	1,470.00	-36.45	-101.21	-4,479.93
Cash from Financing Activities	-9.81	-1,171.00	52.49	72.11	3,976.83
Net Cash Inflow / Outflow	0.01	12.00	72.91	-1.14	94.48

Ratios

Profitability Ratios

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	72.03	-5.50	17.30	33.43	13.06
ROE (%)	0.00	-9.92	8.84	40.51	14.90
ROA (%)	8.76	-3.93	6.36	16.74	7.76
EBIT Margin (%)	18.11	2.55	32.35	23.94	25.21
Net Margin (%)	9.59	-10.46	9.45	15.79	12.89
Cash Profit Margin (%)	16.36	-1.10	19.06	17.08	19.71

Growth Ratios

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	70.32	-4.78	19.65	42.13	0.00
EBIT Growth (%)	374.89	-56.28	3.17	85.90	--
Net Profit Growth (%)	573.31	-115.30	-37.89	96.57	0.00
EPS Growth (%)	573.31	1,097.71	-37.89	-34.47	0.00
Book Value Growth (%)	164.52	26.74	8.89	51.79	0.00

Valuation Ratios

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	0.00	6.12	0.00	0.00	0.00
Price / Book Value	0.00	1.36	0.00	0.00	0.00
Dividend Yield (%)	--	0.00	--	--	--
EV/EBITDA	1.20	95.62	0.14	2.03	2.20
Market Cap (₹ Cr)	0.00	4,557.85	0.00	0.00	0.00

Solvency Ratios

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	4.12	0.70	0.26	0.85	0.52
Short term debt to equity ratio	0.02	0.32	0.12	0.27	0.06
Current Ratio	0.43	0.73	3.02	1.30	1.45
Quick Ratio	0.21	0.47	2.46	0.94	0.97
Interest Coverage	5.98	-1.28	7.74	13.77	6.81

Operating Efficiency Ratios

	Wintac	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	11.43	33.90	43.28	35.43	24.94
Asset Turnover	0.88	0.61	0.65	1.06	0.65
Receivable days	24.76	85.04	160.21	94.89	82.08
Inventory Days	75.59	59.63	58.00	60.39	64.21
Payable days	292.16	255.87	183.24	138.36	162.72
Cash Conversion Cycle	-191.80	-111.19	34.97	16.92	-16.42

Annual
Quarterly